Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review

Authors:

Abstract
Recent advances and drug approvals in the last decade have substantially changed the landscape of relapsed and refractory multiple myeloma (RRMM), with not only improved outcomes for patients, but ...

This publication has 77 references indexed in Scilit: